- $186.70m
- $118.29m
- $7.67m
Brief: Adagene Announces Inclusion In FTSE Russell Indexes
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:50 AM
Brief: Adagene Presents Preclinical Data from Lead SAFEbody Program at AACR Annual Meeting 2021
Brief: Adagene Announces Clinical Advancement For Adg116
Brief: Adagene Announces First Patients Dosed In Global Phase 1 Clinical Trial Of Adg126, Lead Safebody™ Program
U.S. RESEARCH ROUNDUP-Adagene, Costco Wholesale, Ulta Beauty
Brief: Adagene Announces Pricing Of Initial Public Offering
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 04:00 AM